Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 41kWORD 18k
18 April 2019
Question for written answer E-002128-19
to the Commission
Rule 130
Nessa Childers (S&D) , Kateřina Konečná (GUE/NGL)

 Subject:  Access to innovative treatment and care in the EU
 Answer in writing 

Persistent health inequalities remain, across and within the Member States; this issue is considered an urgent priority for the EU health policy agenda. In recent years, the lack of access to treatment and care (including dietary, pharmacological treatment and long-term care) has been increasingly recognised as an important factor in combating health inequalities, since the lack of access results in poorer health outcomes and a lower quality of life.

As Members of the European Parliament, we believe that patients across the EU — in particular those faced with considerable unmet needs e.g. people living with rare diseases — are entitled to equal access and opportunities so they can enjoy the highest attainable quality of health services and care.

Can the Commission indicate how it is responding to increasing calls — from patients, healthcare professionals and other key health and social stakeholders — for better and equal access to treatment and care, including innovative and personalised medicinal products?

Last updated: 6 May 2019Legal notice - Privacy policy